

Special Issue

Avian Viruses and Host Immune System

Message from the Guest Editors

Avian Reovirus is an important pathogen in the poultry industry. Natural immunity is the first line of defense against Avian Reovirus infection. It can activate natural immune signaling pathways, induce IFN and drive downstream antiviral protein expression, which is a key mechanism for the host to clear the virus. The result of this bidirectional action determines the clinical outcome of Avian Reovirus infection: if the host has a healthy immune function (e.g., adult poultry), the virus can be cleared through an efficient immune response, resulting in a latent infection; if the host has an immune deficiency (e.g., young or immunosuppressed birds), the virus continues to replicate, causing viral arthritis, immunosuppression and secondary infections, resulting in economic losses. This Special Issue will examine current research that provides targets for Avian Reovirus prevention and control (such as TLR7, MDA5, IFN pathways) and in the future, by enhancing the activity of these key immune nodes, new prevention and control technologies (such as genetic engineering vaccines, immune enhancers).

Guest Editors

Dr. Tao Yun

Institute of Animal Husbandry and Veterinary Sciences, Zhejiang Academy of Agricultural Sciences, Hangzhou, China

Dr. Chengcheng Zhang

Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China

Deadline for manuscript submissions

1 December 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/264064

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).